Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced stomach cancer: phase 3 trial launches

NCT ID NCT07118527

Recruiting now Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 27 times

Summary

This study tests whether a new drug combination (SHR-A1811 plus chemotherapy and adebrelimab) works better than the current standard treatment for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. About 600 adults aged 18 to 75 will be randomly assigned to one of the two treatment groups. The main goals are to see if the new combo delays cancer growth and helps people live longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC UNTREATED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Hospital of China Medical University

    RECRUITING

    Shenyang, Liaoning, 110001, China

    Contact

  • Zhongshan Hospital，Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

    Contact

Conditions

Explore the condition pages connected to this study.

PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC UNTREATED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA